Journal Club

Because “Good Enough” is Not Ok: Examining the Need for Novel Therapies in the Management of EDS in OSA and Narcolepsy

Launch Date
02/26/2021 at 8:00 am EST
Credit Amount
0.00 Expired
Credit Expires
02/26/2022
This activity is part of a series

Faculty

Richard K. Bogan, MD, FCCP, FAASM
Associate Clinical Professor
University of South Carolina Medical School
Columbia, SC
Medical University of South Carolina
Charleston, SC
Principal, Bogan Sleep Consultants, LLC
Columbia, SC
Richard K. Bogan, MD, FCCP, FAASM

Dr. Bogan is the President of Bogan Sleep Consultants, LLC. He is also Associate Clinical Professor at the University of South Carolina School of Medicine and Associate Clinical Professor at the Medical University of South Carolina in Charleston, SC.

Dr. Bogan received his bachelor’s degree in chemistry from Wofford College and his MD degree from the Medical University of South Carolina in Charleston. He served his internship and residency, as well as Chief Medical Resident, at the University of Alabama Hospital and Clinics in Birmingham. Thereafter, he completed a fellowship and assistant professorship in the Pulmonary Division of the Department of Medicine at the University of Alabama School of Medicine. He has been certified by the American boards of Sleep Medicine, Internal Medicine, and Pulmonary Diseases.

Dr. Bogan has served as principal investigator on numerous clinical trials in the past and continues to do so now. He has a variety of publications and research interests that focus on topics such as narcolepsy, insomnia, sleep apnea, shift work sleep disorder, restless legs syndrome/periodic limb movement disorder, chronic fatigue/fibromyalgia, and circadian rhythm abnormality.

Michael J. Thorpy, MD
Professor of Neurology, Albert Einstein College of Medicine
Director, Sleep-Wake Disorders Center, Department of Neurology
Montefiore Medical Center, Bronx, NY
President, New York State Society of Sleep Medicine
Past President, Sleep Section of the Academy of Neurology
Michael J. Thorpy, MD

Dr. Thorpy is a Professor of Neurology at Albert Einstein College of Medicine and Director of the Sleep-Wake Disorders Center in the Department of Neurology at Montefiore Medical Center, both in New York. In addition to treating patients with sleep disorders, he conducts research in narcolepsy, insomnia, and sleep apnea. He is President of the New York State Society of Sleep Medicine, Past President of the Sleep Section of the Academy of Neurology, and Past Secretary of the National Sleep Foundation. In 1993 Dr. Thorpy received the Nathaniel Kleitman Award from the American Academy of Sleep Medicine, one of the field’s highest honors, and in 2012 he received the Lifetime Achievement Award from the National Sleep Foundation.

Born in New Zealand, Dr. Thorpy earned his medical degree from the University of Otago Medical School. After receiving postgraduate training in Dunedin, New Zealand; Bombay, India; and London, England, he completed his residency in neurology at the State University of New York in Syracuse and a neuroendocrinology fellowship at Albert Einstein College of Medicine and Montefiore Medical Center. Dr. Thorpy is board certified in sleep medicine.

He has published extensively on narcolepsy, insomnia, and sleep disorders. He chaired the first International Classification of Sleep Disorders and has published more than 250 peer-reviewed articles and chapters, including publications in journals such as The New England Journal of Medicine. His numerous books include The Encyclopedia of Sleep and Sleep Disorders, Parasomnias (2010), Sleepiness (2011), Neuroimaging of Sleep and Sleep Disorders (2012), Genetics of Sleep and Sleep Disorders (2013), Narcolepsy: a Clinical Guide (2016), and SleepMultiMedia, The Computerized Textbook of Sleep Medicine (v12).0 (2023).

Dr. Thorpy has given more than 100 television, radio, and print interviews on sleep disorders.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Additional Formats

Statement of Need

Current agents used to treat excessive daytime sleepiness (EDS) do not always lead to ideal treatment outcomes. Given the limitations in safety and efficacy of more traditional therapies for EDS, there is a need for novel therapies.

In this second installment of a 3-part journal club series on making sense of the latest clinical data on EDS in obstructive sleep apnea (OSA) and narcolepsy, featuring expert faculty discussing the factors to consider when making treatment selections for patients and how best to personalize treatment strategies, including which patients would be ideal for JZP-258, transitioning patients from one therapy to another, and dosing considerations.

Learning Objectives

At the end of this CME/CE activity, participants should be able to analyze the need for novel therapies for EDS given limitations in safety and efficacy of current therapies.

Financial Support

Supported by an educational grant from Jazz Pharmaceuticals, Inc.

Target Audience

Sleep specialists, pulmonologists, PCPs, PAs, NPs, nurses, pharmacists.

Credit Information

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABPN MOC

ABPN Diplomates may select any CME activity relevant to their practice to count towards ABPN MOC requirements.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit ™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit ™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to PAs

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit ™ from organizations accredited by the Accreditation Council for Continuing Medical Education.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Bogan reports that he receives grants from Axsome Therapeutics, Inc.; Eisai Inc.; Flamel Technologies; Fresca Medical, Inc.; Harmony Biosciences, LLC; Idorsia Pharmaceuticals; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Philips; Suven Life Sciences; and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He is on the speakers bureau for Eisai Inc.; Harmony Biosciences, LLC; and Jazz Pharmaceuticals, Inc.

Dr. Thorpy reports that he is a consultant or on the advisory board for Axsome Therapeutics, Inc.; Balance Therapeutics; Eisai Inc.; Flamel Technologies/Avadel; Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc.; Suven Life Sciences Limited; and Takeda Pharmaceutical Company Limited.

  • Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.
  • Evan Luberger (planning committee) has no disclosures to report.
  • Jan Perez (planning committee) has no disclosures to report.
  • Sharon Tordoff (planning committee) has no disclosures to report.
  • Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Additional Formats

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-21-104-H01-P

 

Questions about this activity?

Call us at (877) CME-PROS or (877) 263-7767.

 

JC-020-022621-43

Because “Good Enough” is Not Ok: Examining the Need for Novel Therapies in the Management of EDS in OSA and Narcolepsy
Event Date: 02/26/2021 at 8:00 am EST

Activities in the Series

03/15/2021

Lose a Little Sleep, Lose a Lot of Life

0.00 Expired
Learn More
01/01/2023 at 8:00 am EST

Putting Data into Practice: Applying the Latest Clinical Evidence to Management Strategies

0.00 Expired
Learn More